Sharp Brains: Brain Fitness and Cognitive Health News

Neuroplasticity, Brain Fitness and Cognitive Health News

Icon

Drugs for Early-Stage Alzheimer’s?

Medical-warning-label-concept--42312982Drugs for Early-Stage Alzheimer’s (good New York Times editorial):

“The Food and Drug Administration has proposed lowering the bar for approving drugs to treat people at the earliest stages of Alzheimer’s disease, before they have developed any serious impairment or overt dementia. The goal is commendable — to find ways to prevent or slow the progression of this terrible disease before it can rob people of their mental capacities. But the proposal raises troubling questions as to whether the agency would end up approving drugs that provide little or no clinical benefit yet cause harmful side effects in people who take the medications for extended periods…Independent analysts need to look hard at whether the F.D.A. should lower the bar for these drugs — or should demand a very high level of proof of safety and effectiveness before exposing still-healthy people to possible harm. Even if drugs are eventually approved under this new approach, it will be imperative to force manufacturers to conduct follow-up studies, as required by law, to see if patients benefit in the long run. This is a task they are often slow to perform once a drug is on the market.”

Pic courtesy of BigStockPhoto

Leave a Reply...

Loading Facebook Comments ...

Leave a Reply

Categories: Cognitive Neuroscience, Health & Wellness

Tags: , , , ,

Learn more & Register today at early-bird rates

2016 SharpBrains Virtual Summit: Reinventing Brain Health

About SharpBrains

As seen in The New York Times, The Wall Street Journal, CNN, and more, SharpBrains is an independent market research firm tracking applied brain science. Explore our most popular resources HERE.

Search for anything brain-related in our article archives